Loading stock data…
CNXU
$13.94-1.22 (-8.06%)
Pre-Market$12.85-1.09 (-7.82%)· Last close Jun 9
Conexeu Sciences Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$1.72M↓ | -$332,721 |
| Net Income | -$1.72M↓ | -$290,064 |
Peer Comparison
JNJUNHPFE
Fundamentals
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (E...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.43%
Volume
Today's trading volume
84,012
Recent News
Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
Weiss Ratings analyst Chris Graebe outlines how Regulation A offerings let retail investors access private companies like FJET, NUCL, and CNXU before their public listings.
How Investors Are Reacting To Conexeu Sciences (CNXU) 3D-Printed Bioregenerative Breast Matrix Initiative
Conexeu Sciences Inc. recently initiated a preclinical development program at the Wake Forest Institute for Regenerative Medicine for B.R.E.A.S.T., a 3D-printed bioregenerative breast matrix built on its proprietary CXU extracellular matrix platform. The collaboration taps advanced tissue-organ bioprinting infrastructure to explore a resorbable, cell-guiding alternative to permanent breast implants, with potential to extend CXU technology across multiple medical and aesthetic markets. We...